Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsSeth Lerner, MD
Assistant Clinical ProfessorAbout
Research
Publications
2026
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non–muscle-invasive Bladder Cancer
Linehan J, Agarwal P, Penny X, Kates M, Jacob J, Lerner S, Kines R, Schiller J, de los Pinos E, Shore N, Hopkins J, McQuaid J, Brookman-May S. Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non–muscle-invasive Bladder Cancer. European Urology Open Science 2026, 89: 77-88. PMID: 42325814, PMCID: PMC13279200, DOI: 10.1016/j.euros.2026.05.017.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerTransurethral resectionIntermediate-riskUntreated tumorsBladder cancerTransurethral resection of bladder tumorMemory CD4+ T cellsGrade 1 adverse eventsResection of bladder tumorTertiary lymphoid structure formationCD4+ T cellsPaired tumor specimensAntitumor immune responseDose-limiting toxicityLow-grade tumorsLocal tumor eradicationPhase 1 studyNatural killer cellsTumor cell deathShort follow-upComplete responseBladder tumorsTumor specimensTumor eradicationFirst interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
Nappi L, Colby S, Hamilton R, Harzstark A, Adra N, Daneshmand S, Ryan C, Eggener S, Fung C, Johnson R, Lerner S, Arnold K, Arun B, Rae J, Blanke C, LeBlanc M, Parulekar W, Einhorn L, Kollmannsberger C, Nichols C, Investigators O. First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer. Journal Of Clinical Oncology 2026, 44: lba5003-lba5003. DOI: 10.1200/jco.2026.44.17_suppl.lba5003.Peer-Reviewed Original ResearchActive surveillanceInterim analysisProspective dataInternational prospective cohort studyGerm cell malignanciesMicroRNA-371a-3pGerm cell tumorsEarly stage diseaseEarly-stage testicular cancerNegative predictive valueProspective cohort studyRelapsed 3Data cutoffTumor relapseEligible ptsStage diseaseCell tumorsOperating characteristicsMedian timeRetrospective studyTesticular cancerCell malignancyRelapseCohort studyGroup NCorrelation of baseline testosterone (T) level with survival outcomes in patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)–level data from SWOG 1216 study.
Gebrael G, Jo Y, Tangen C, Nandakumar V, Ozay Z, Li H, Goel K, Plets M, Hussain M, Dorff T, Goldkorn A, Lara P, Lerner S, Swami U, Agarwal N. Correlation of baseline testosterone (T) level with survival outcomes in patients (Pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)–level data from SWOG 1216 study. Journal Of Clinical Oncology 2026, 44: 5096-5096. DOI: 10.1200/jco.2026.44.16_suppl.5096.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerPSA responseProgression-free survivalProstate-specific antigenT levelsBaseline T levelsPrognostic impactSurvival outcomesStandard armPSA response rateProgression-free survival medianHormone-sensitive prostate cancerBaseline TAssociated with inferior survival outcomesBaseline serum TInferior survival outcomesLog-rank testHypothesis-generating dataPhase 3 trialClinical trial populationsMedian T levelsPearson chi-square testPatient-level analysisStatistically significant associationOS medianEvaluating and validating immune effector dysfunction as a biomarker in bladder cancer.
Safa H, Pourebrahim R, Anurag M, Holt M, Yen A, Lerner S, Rutella S, Luznik L. Evaluating and validating immune effector dysfunction as a biomarker in bladder cancer. Journal Of Clinical Oncology 2026, 44: e16601-e16601. DOI: 10.1200/jco.2026.44.16_suppl.e16601.Peer-Reviewed Original ResearchCheckpoint inhibitorsMultivariate Cox regressionTCGA-BLCAMolecular subtypesBaylor College of MedicineBladder cancerOverall survivalAssociated with inferior median OSInferior median progression-free survivalCox regressionMedian progression-free survivalCPI responseInferior median OSProgression-free survivalT cell exhaustionResponse to immunotherapyCheckpoint inhibitor efficacyAcute myeloid leukemiaBladder cancer treatmentMedian OSPapillary tumorsAggressive diseasePrognostic indexPrognostic significanceMyeloid leukemiaTRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924).
Ong M, Sokolova A, Hotte S, Dorff T, N. K, Wyatt A, Goldkorn A, Kolinsky M, Brundage M, Ndika A, Lerner S, Parulekar W, Ding K, Jafri M. TRIPLE-SWITCH (SWOG/CCTG-PR26): A randomized phase III clinical trial for the addition of docetaxel to androgen receptor pathway inhibitors in patients with metastatic castration sensitive prostate cancer (mCSPC) and suboptimal PSA response (NCT06592924). Journal Of Clinical Oncology 2026, 44: tps5149-tps5149. DOI: 10.1200/jco.2026.44.16_suppl.tps5149.Peer-Reviewed Original ResearchAndrogen receptor pathway inhibitorsMetastatic castration sensitive prostate cancerAndrogen deprivation therapyOverall survivalPSA responsePredictive value of circulating tumor DNADocetaxel to androgen deprivation therapyResponse to androgen deprivation therapyAndrogen deprivation therapy initiationCastration sensitive prostate cancerClinical progression free survivalPoorer median overall survivalStandard androgen deprivation therapyECOG performance status 0Pathway inhibitorRandomized phase III trialPresence of liver metastasesAbsence of randomized dataRandomized phase III clinical trialsPredictive valuePhase III clinical trialsMedian overall survivalPerformance status 0Toxicity of docetaxelProgression free survivalNarrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Kim S, Gudlavalleti H, Lerner S. Narrative Review of Potential Non-Surgical Treatments for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Journal Of Clinical Medicine 2026, 15: 3830. PMID: 42194790, PMCID: PMC13208041, DOI: 10.3390/jcm15103830.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerInvasive bladder cancerBacillus Calmette-GuerinRadical cystectomyBladder cancerBCG-unresponsive NMIBCAlternative to radical cystectomyIntravesical bacillus Calmette-GuerinProgression to MIBCTherapeutic agentsNon-surgical treatmentNarrative reviewBladder preservationBCG therapyDisease recurrencePostoperative morbidityPrognostic efficacyInvasive therapyTherapeutic regimensTreatment optionsTumor cellsTherapeutic efficacyClinical trialsDisease progressionCystectomyCigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression
Amara C, Piyarathna D, Kamal A, San Chan Y, Reddy K, Ambati C, Hassan M, Shriwas P, Gandhi T, Jain A, Gangnus T, Popli P, Borkar R, Kang S, Summers S, Putluri V, Grimm S, Venkatesh S, Song N, Seeley E, Hedlich-Dwyer J, Chen S, Mahajan N, Jain A, Dobrolecki L, Wells G, Villanueva H, Li J, Liu X, Bollag R, Malovannaya A, Jung S, Lee H, Asangani I, Terris M, Creighton C, Ballester L, Karanam B, Liu S, Lee M, Raju R, Siddiqui M, Eberlin L, Kommagani R, Sreekumar A, Gao J, Young N, Hodges H, Coarfa C, Gassman N, Lerner S, Lotan Y, Putluri N. Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression. Cancer Letters 2026, 653: 218562. PMID: 42092682, PMCID: PMC13241086, DOI: 10.1016/j.canlet.2026.218562.Peer-Reviewed Original ResearchDNA-binding transcription factorsFatty acid biosynthesisCancer cell survivalFatty acid synthesisElevated fatty acid levelsCigarette smokingBladder cancer cellsBladder cancerTumor growthAcid biosynthesisReductive carboxylationMetabolic rewiringTranscription factorsHistone acetylationDNA repairBladder cancer progressionEpigenetic alterationsAcid synthesisMetabolic shiftCarbon sourceMetabolic pathwaysCell survivalFASN inhibitorsBladder tumor growthCancer cellsLeveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer
Kamal A, Putluri V, Gandhi T, Ambati C, Amara C, Kami Reddy K, Spradlin M, Koirala A, Jorvekar S, Grimm S, Fu D, Parsawar K, Jong F, Beecher C, Sen S, Lerner S, Siddiqui M, Lotan Y, Eberlin L, Sreekumar A, Coarfa C, Putluri N. Leveraging untargeted metabolomics in combination with machine learning to uncover novel insights into bladder cancer. Cancer & Metabolism 2026, 14: 8. PMID: 41923172, PMCID: PMC13040883, DOI: 10.1186/s40170-026-00427-4.Peer-Reviewed Original ResearchComprehensive metabolic profilingUntargeted metabolomicsBladder cancerMS/MS spectral libraryOrbitrap mass spectrometryNon-muscle-invasive bladder cancerMetabolite annotationMass spectrometryIdentification of novel pathwaysMetabolic landscapeTherapeutically targetable pathwaysDevelopment of precision diagnosticsMuscle-invasivePredictive biomarkersPrognostic valueMetabolic markersMetabolic signaturesMetabolic vulnerabilitiesMetabolomicsSpectral libraryNormal/benign samplesTherapeutic strategiesCancer progressionCancerEarly detectionRadiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis
Boyne A, Anderson R, Liu D, Varghese B, Lei X, Hwang D, King K, Dani K, Cen S, Duddalwar V, Lerner S. Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis. Bladder Cancer 2026, 12: 23523735261455396. PMID: 42221944, PMCID: PMC13219846, DOI: 10.1177/23523735261455396.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerTumor mutational burdenBladder cancerTranscriptome profilingComputed tomographyCT-based texture analysisRadiogenomic analysisHigh-TMB tumorsCT-derived radiomic featuresUrothelial bladder cancerGenomic dataCancer Genome AtlasPrognostic relevanceRecurrent mutationsDNA mutationsMutational burdenClinically relevant informationRecurrent alterationsCell cycleMolecular subtypesTumor biologyNoninvasive adjunctCancer Imaging ArchiveGenomic profilingMolecular testingEnfortumab Vedotin plus Pembrolizumab as Perioperative Therapy
Singh P, Lerner S. Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy. The New England Journal Of Medicine 2026, 394: 1334-1336. PMID: 41707168, DOI: 10.1056/nejme2515777.Peer-Reviewed Original Research